Figure 4.
LipocyteProfiler identifies molecular mechanisms of drug stimulations in adipocytes and hepatocytes
(A) LipocyteProfiler was performed in visceral AMSCs (n = 3) treated with the β-adrenergic receptor agonist isoproterenol for 24 h.
(B) Isoproterenol treatment results in changes of lipid-related and mitochondrial traits in visceral AMSCs at day 14 of differentiation. See also Figure S3B (volcano plot reporting the −log10 p value and the effect comparing isoproterenol-treated cells and DMSO-treated cells, t test).
(C and D) Isoproterenol treatment of visceral AMSCs increase Mito and Lipid TextureDifferenceVariance while decreasing the respective LargeLipidObject mean radius features. y axis shows LP units (normalized LP values across eight batches, see STAR Methods).
(E) Isoproterenol treatment reduces lipid-droplet sizes measured via lipid granularity. y axis shows autoscaled LP units (normalized LP values across eight batches, see STAR Methods).
(F) Oleic acid treatment in PHH results in changes of lipid-related features.
(G) Oleic acid treatment in PHH affects lipid-related morphological features suggestive of increased lipid-droplet size and number. y axis shows LP units (normalized LP values across PHH data, see STAR Methods).
(H) Metformin treatment in PHH results in global changes affecting features across all channels.
(I) Metformin effect in hepatocytes is suggestive of increased mitochondrial activity, while lipid-droplet size and number are reduced. Metformin-treated hepatocytes are also smaller and show reduced cytoskeletal randomness. y axis shows LP units (normalized LP values across PHH data, see STAR Methods).